Zhejiang Seefunge Pharmaceutical Technology

Zhejiang Seefunge Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Hangzhou, China, dedicated to the development of innovative small molecule therapeutics. The company focuses on metabolic disorders and oncology, leveraging its expertise in medicinal chemistry to create differentiated drug candidates. Its lead program, SFG-001, is a potent and selective URAT1 inhibitor currently in Phase 2 clinical trials for the treatment of hyperuricemia and gout. Seefunge's R&D strategy emphasizes the optimization of molecular structures to enhance efficacy while minimizing off-target toxicities. The company has successfully secured significant venture capital funding to advance its pipeline toward commercialization.